August 12, 2018: Execution of the Collaborative Development License and Exclusive Option Agreement for anti-Semaphorin 3A antibody developed by Chiome Bioscience Chiome Bioscience Inc. (hereinafter, “Chiome”) announced today that it has executed a...
← Precious Next → SemaThera Announces a $2MUS Financing and a Licensing Deal for China and Japan MONTREAL–(BUSINESS WIRE)–SemaThera Inc announces today the closing of a $2MUS co-investment from Senju Pharmaceutical Co., Ltd. and AmorChem L.P. for the...
Next → AmorChem spins out its SEMA 3A technology into SemaThera, with 1m$ seed investment Montreal, Quebec – January 11, 2017 – AmorChem is pleased to announce the creation of SemaThera, its second spin-off company focusing on a novel therapeutic approach to...
